Loading...
XNAS
XBIO
Market cap5mUSD
Jul 15, Last price  
3.74USD
1D
-8.04%
1Q
47.58%
Jan 2017
-99.29%
IPO
-99.13%
Name

Xenetic Biosciences Inc

Chart & Performance

D1W1MN
P/E
P/S
2.27
EPS
Div Yield, %
Shrs. gr., 5y
40.13%
Rev. gr., 5y
171.13%
Revenues
3m
-1.56%
293,6031,000,000003,000,0007,585,000017,066436,9421,160,6921,706,9252,539,9862,500,284
Net income
-4m
L-4.22%
-6,328,340-8,579,246-14,307,104-12,507,471-54,206,106-3,595,132-7,300,458-15,949,915-10,893,466-5,544,712-6,386,798-4,134,578-3,960,275
CFO
-3m
L-31.52%
-6,262,054-6,052,022-12,329,096-5,300,726-8,787,1751,494,195-6,463,957-6,399,404-4,267,193-4,738,067-4,646,765-4,114,219-2,817,478
Earnings
Aug 11, 2025

Profile

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
IPO date
Nov 07, 2016
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,500
-1.56%
2,540
48.80%
1,707
47.06%
Cost of revenue
6,705
7,056
8,452
Unusual Expense (Income)
NOPBT
(4,204)
(4,516)
(6,745)
NOPBT Margin
Operating Taxes
(166)
Tax Rate
NOPAT
(4,204)
(4,516)
(6,579)
Net income
(3,960)
-4.22%
(4,135)
-35.26%
(6,387)
15.19%
Dividends
Dividend yield
Proceeds from repurchase of equity
16
1,294
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
287
Net debt
(6,166)
(8,983)
(13,097)
Cash flow
Cash from operating activities
(2,817)
(4,114)
(4,647)
CAPEX
(500)
Cash from investing activities
(500)
Cash from financing activities
FCF
(4,204)
(4,516)
(6,579)
Balance
Cash
6,166
8,983
13,097
Long term investments
Excess cash
6,041
8,856
13,012
Stockholders' equity
(196,939)
(192,977)
(188,828)
Invested Capital
202,946
202,773
202,475
ROIC
ROCE
EV
Common stock shares outstanding
1,541
1,528
1,422
Price
Market cap
EV
EBITDA
(4,204)
(4,516)
(6,718)
EV/EBITDA
Interest
166
Interest/NOPBT